IL17A and colitis: G1: NSAIDs/sacroiliac corticosteroid. Continuation of ICIsG2: NSAIDs/sacroiliac corticosteroid with or without bDMARDs (anti-TNF, anti-IL-12/23, and JAKi; avoid anti-IL-17 when colitis).Temporal discontinuation of ICIs until G0/G1G3–4: NSAIDs/sacroiliac corticosteroid with bDMARDs (TNFi, anti-IL-12/23, and JAKi; avoid anti-IL-17 when colitis). ICIs cessation